NGNENeurogene Inc
$26.49
$0.99
(3.60%)
Closed $26.49
$0.00
(0.00%)
After Hours
Reported EarningsMay 12
Mkt Cap$418.59M
Vol67,356.00
Fundamentals
Mkt Cap
$418.59M
Volume
-
52W High
$37.27
52W Low
$14.65
PE Ratio
-5.28
Avg. Volume
140,231.70
EPS (Annual)
-$4.24
Rev/Employee
$0.00
Earnings
May 12
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Companys Board of Directors approved the grant of non-qualified stock...
Business Wire
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter...
Business Wire
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, highlighted data at the...
Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the...
Business Wire
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight research firms that are covering the stock, Marketbeat reports...
MarketBeat
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an upcoming...
Business Wire
Neurogene (NASDAQ:NGNE) Shares Up 0.1% - Here's What Happened
Neurogene (NASDAQ:NGNE) Stock Price Up 0.1% - What's Next...
MarketBeat
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to...
Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the...
Business Wire
Neurogene (NASDAQ:NGNE) Given New $180.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group reduced their price target on shares of Neurogene from $200.00 to $180.00 and set a "buy" rating on the stock in a research report on Monday...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest NGNE News
ViewNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Business Wire
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Business Wire
Advertisement|Remove ads.